Cover Image
市場調查報告書

破傷風 : 開發中產品分析

Tetanus - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192846
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
破傷風 : 開發中產品分析 Tetanus - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 73 Pages
簡介

所謂破傷風是破傷風菌所引起的嚴重疾病。主要的前兆·症狀有下巴肌肉的痙攣和僵直化,吞嚥障礙,腹肌僵直化,發熱,發汗,血壓·心律上升等。易罹病素質包含了燒燙傷,及外科手術造成的外傷,耳朵的感染疾病,外傷部分附近的水腫,足部潰瘍(的感染)等。主要的治療藥有抗生素和鎮靜劑,乙型阻斷劑等。

本報告提供全球各國治療破傷風所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

破傷風概要

治療藥的開發

  • 破傷風開發中產品:概要
  • 破傷風開發中產品:比較分析

各企業開發中的破傷風治療藥

大學/研究機關研究中的破傷風治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

破傷風治療藥:開發中的產品的一覽(各企業)

破傷風治療藥:研究中的產品的一覽(各大學/研究機關)

破傷風開發治療藥的企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • BioClonetics Immunotherapeutics, Inc.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Indian Immunologicals Limited
  • 化學和血清療法學會(化血研)
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

破傷風:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各投藥法
  • 各分子類型

藥物簡介

破傷風治療藥:開發暫停的產品

破傷風治療藥:開發中止的產品

破傷風相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9196IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Pipeline Review, H1 2017, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 3, 6, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tetanus - Overview
    • Tetanus - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Tetanus - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tetanus - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Bharat Biotech International Ltd
    • Biological E Ltd
    • Boryung Pharmaceutical Co Ltd
    • Daiichi Sankyo Company Ltd
    • GlaxoSmithKline Plc
    • Green Cross Corp
    • Indian Immunologicals Ltd
    • Kaketsuken KK
    • LG Chem, Ltd.
    • Panacea Biotec Ltd
    • Prometheon Pharma LLC
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Shantha Biotechnics Ltd
    • Zydus Cadila Healthcare Ltd
  • Tetanus - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-1107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3111A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tetanus - Dormant Projects
  • Tetanus - Discontinued Products
  • Tetanus - Product Development Milestones
    • Featured News & Press Releases
      • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tetanus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Tetanus - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Tetanus - Pipeline by Biological E Ltd, H1 2017
  • Tetanus - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
  • Tetanus - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Tetanus - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Tetanus - Pipeline by Green Cross Corp, H1 2017
  • Tetanus - Pipeline by Indian Immunologicals Ltd, H1 2017
  • Tetanus - Pipeline by Kaketsuken KK, H1 2017
  • Tetanus - Pipeline by LG Chem, Ltd., H1 2017
  • Tetanus - Pipeline by Panacea Biotec Ltd, H1 2017
  • Tetanus - Pipeline by Prometheon Pharma LLC, H1 2017
  • Tetanus - Pipeline by Sanofi Pasteur SA, H1 2017
  • Tetanus - Pipeline by Serum Institute of India Ltd, H1 2017
  • Tetanus - Pipeline by Shantha Biotechnics Ltd, H1 2017
  • Tetanus - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Tetanus - Dormant Projects, H1 2017
  • Tetanus - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Tetanus - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Tetanus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top